CDK4/6 Inhibitors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer

The authors discuss potential resistance mechanisms to CDK4/6 inhibitors, the use of biomarkers to guide treatment for hormone receptor-positive, HER2– negative metastatic breast cancer and possible approaches to overcome resistance to CDK4/6 inhibitors.